TrialRheumatology (Oxford, England)2026

Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.

Ming-Hui Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.